Book Review: Neuroscience for psychologists and other mental health professionals

American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Washington, DC: Author.

Bola J. R. (2006a). Psychosocial acute treatment in early-episode schizophrenia disorders. Research on Social Work Practice, 16, 263–275.

Bola J. R. (2006b). Medication-free research in early episode schizophrenia: Evidence of long-term harm? Schizophrenia Bulletin, 32, 288–296.

Bola J. R. Kao D. T. Soydan H. (2012). Cochrane corner: Antipsychotic medications for early-episode schizophrenia. Schizophrenia Bulletin, 38, 23–25.

Bola J. R. Lehtinen K. Aaltonen J. Räkköläinen V. Syvälahti E. Lehtinen V. (2006). Predicting medication-free treatment responders in acute psychosis: Cross-validation from the Finnish Need-Adapted project. Journal of Nervous and Mental Disease, 194, 732–739.

Bola J. R. Lehtinen K. Cullberg J. Ciompi L. (2009). Psychosocial treatment, antipsychotic postponement, and low-dose medication strategies in first episode psychosis Psychosis: Psychological, Social and Integrative Approaches, 1, 4–18.

Bola J. R. Mosher L. R. (2002). Predicting drug-free treatment response in acute psychosis from the Soteria project. Schizophrenia Bulletin, 28, 559–575.

Chouinard G. Jones B. D. Annable L. (1978). Neuroleptic-induced supersensitivity psychosis. American Journal of Psychiatry, 135, 1409–1410.

Conrad P. Schneider J. W. (1992). Deviance and medicalization: From badness to sickness (expanded Ed.). Philadelphia, PA: Temple University Press.

Engel G. L. (1977). The need for a new medical model: A challenge for biomedicine. Science, 196, 129–136.

Frances A. (2013). Saving normal: An insiders revolt against out-of-control psychiatric diagnosis, DSM-5, big pharma, and the medicalization of ordinary life. New York, NY: Harper Collins.

Francey S. M. Nelson B. Thompson A. Parker A. G. Kerr M. MacNeil C. … McGorry P. D. (2010). Who needs antipsychotic medication in the earliest stages of psychosis? A reconsideration of benefits, risks, neurobiology and ethics in the era of early intervention. Schizophrenia Research, 119, 1–10.

Gaebel W. Weinmann S. Sartorius N. Rutz W. McIntyre J. S. (2005). Schizophrenia practice guidelines: International survey and comparison. British Journal of Psychiatry, 187, 248–255.

Garcia G. Sunil T. S. Hinojoso P. (2012). The fast food and obesity link: Consumption patterns and severity of obesity. Obesity Surgery, 22, 810–818.

Hafner H. (1985). Are mental disorders increasing over time? Psychopathology, 18, 66–81.

Hegarty J. D. Baldessarini R. J. Tohen M. Waternaux C. Oepen G. (1994). One hundred years of schizophrenia: A meta-analysis of the outcome literature. American Journal of Psychiatry, 151, 1409–1416.

Ho B.-C. Andreasen N. C. Ziebell S. Pierson R. Magnotta V. (2011). Long-term antipsychotic treatment and brain volumes. Archives of General Psychiatry, 68, 128–137.

Hopper K. Harrison G. Janca A. Sartorius N. (Eds.). (2007). Recovery from schizophrenia: An international perspective. A report from the WHO Collaborative Project, the International Study of Schizophrenia. New York, NY: Oxford University Press.

Kessler R. C. Berglund P. Demler O. Jin R. Walters E. E. (2005). Lifetime prevalence and age-of-onset distributions’ of DSM-IV disorders in the national comorbidity survey replication. Archives of General Psychiatry, 62, 593–602.

Kisely S. Scott A. Denney A. Simon G. (2006). Duration of untreated symptoms in common mental disorders: Association with outcomes. British Journal of Psychiatry, 189, 79–80.

Weick A. Rapp C. Sullivan W. P. Kisthardt W. (1989). A strengths perspective for social work practice. Social Work, 34, 350–354.

Whitaker R. (2010). Anatomy of an epidemic: Magic bullets, psychiatric drugs and the astonishing rise of mental illness in America. New York, NY: Random House.